Impact of four times daily dosing of oral treprostinil on tolerability and daily dose achieved in pulmonary hypertension
Sign Up to like & getrecommendations! Published in 2018 at "Pulmonary Circulation"
DOI: 10.1177/2045893217744512
Abstract: Oral treprostinil (TRE) is a prostacylin that is approved for the treatment of patients with pulmonary arterial hypertension (PAH). Dosing is approved for two or three times daily (t.i.d.); however, adverse effects, including gastrointestinal-related symptoms,… read more here.
Keywords: oral treprostinil; daily dose; times daily; hypertension ... See more keywords